

RECEIVED
CENTRAL FAX CENTER

SEP 28 2004

PATENT CASE CV01148KB US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Examiner: Sudhaker B. Patel
S. Chackalamannil *et al.*) Group Art Unit: 1624
Serial No.: 10/777,849)
Filed: February 12, 2004) Atty. Docket No.: CV01148KB

For: XANTHINE PHOSPHODIESTERASE V INHIBITORS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mailstop: RCE

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the documents listed on the accompanying PTO Form 1449 be considered and made of record in the above-identified patent application. These are the same references that were disclosed in the parent case, Serial No. 09/940,760. No additional references are herein disclosed.


In accordance with MPEP §609 (I) (B) (3) (Rev. 2, May 2004), Applicants are not submitting the cited references. However, Applicants will gladly provide any references requested.

Since this disclosure is being submitted contemporaneously with the Request for Continued Examination, Applicants do not believe that the filing of this Information Disclosure Statement necessitates a fee. However, should any fees become necessary for the consideration of the references cited in this disclosure, the Commissioner is hereby petitioned to charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

September 28, 2004
Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1,1990
Kenilworth, NJ 07033
Tel: (908) 298-2960
Fax: (908) 298-5388

Respectfully submitted,


Gerard E. Reinhardt
Attorney for Applicants
Reg. No. 43,041

46852_1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.: CV01148KB	SERIAL NO.: 10/777,849	
				APPLICANT: Chackalamannil et al.		
				FILING DATE: 02/12/2004	GROUP: 1624	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AB	5,250,534	10/05/1993	Bell et al.	514	258	
AC	5,256,766	10/26/1993	Coughlin	630	327	
AD	5,321,029	06/14/1994	Maschler et al.	514		
AE	5,346,901	09/13/1994	Bell et al	514		
AF	5,393,755	02/28/1995	Neustadt et al.	514		
AG	5,409,934	04/26/1995	Smith et al.	514		
AH	5,470,579	11/28/1995	Bonte et al.	424		
AI	5,637,593	06/10/1997	Porter et al.	514		
AJ	5,688,768	11/18/1997	Coughlin et al	514	15	
AK	5,719,283	02/17/1998	Bell et al	544	262	
AL	5,769,994	06/02/1998	Coughlin et al	514	9	
AM	5,798,248	08/26/1998	Coughlin et al	435	214	
AN	5,824,683	10/20/1998	McKittrick et al	514	257	
AO	5,856,448	01/05/1999	Coughlin	630	388.22	
AP	5,859,006	01/12/1999	Daugan	514	249	
AQ	5,874,437	02/23/1999	Garvey et al	514	258	
AR	5,877,216	03/02/1999	Place et al	514	573	
AS	5,939,419	08/17/1999	Tulshian et al	514	257	
AT	5,955,611	09/21/1999	Dunn et al.	544		
AU	5,958,926	09/28/1999	Garvey et al	514	253	
AV	5,981,527	11/09/1999	Daugan et al	514		
AW	5,981,563	11/09/1999	Lowrey, Fred	514	250	
AX	6,023,640	02/08/2000	Ross, Jesse	607		
AY	6,024,936	02/15/2000	Coughlin et al	424	1,49	
AZ	6,025,494	02/15/2000	Daugan	546	64	
BA	6,037,346	03/14/2000	Doherty, Jr. et al	514	258	
BB	6,051,594	04/18/2000	Lowrey, Fred	514		
BC	6,066,735	05/23/2000	Dunn et al.	544		
BD	6,087,362	07/11/2000	EI-Rashidy, Ragab	514		
BE	6,100,270	08/08/2000	Campbell	514	258	
BF	6,124,101	09/26/2000	Coughlin	435	7.1	
BG	6,140,329	10/31/2000	Daugan	514	250	
BH	6,143,746	11/07/2000	Daugan et al	514	249	
BI	6,197,541 B1	03/06/2001	Coughlin	435	69.1	
BJ	6,362,178 B1	03/26/2002	Niewöhner et al	514	218	
BK	6,403,597 B1	06/11/2002	Wilson et al	514	256	
BL	6,469,012 B1	10/22/2002	Ellis et al	514	258	
BM	6,469,016 B1	10/22/2002	Place et al	514	262	
BN	6,472,434 B1	10/29/2002	Place et al	514	573	
BO	6,512,002 B2	01/28/2003	Lee et al	514	427	

Page 2 of 6

FOREIGN PATENT DOCUMENTS					CLASS	SUB-CLASS	TRANSLATION	
	CA CB	DOCUMENT NUMBER	DATE	COUNTRY			YES	NO
	CC	EP 0 258 191 A1	02.03.88	EPO				
	CD	EP 0 389 282 A2	26.09.90	EPO				
	CE	EP 0 463 756 A1	02.01.92	EPO				
	CF	EP 0 389 282 A2	26.09.90	EPO				
	CG	EP 0 389 282 A3	26.09.90	EPO				
	CH	EP 0 389 282 B1	26.09.90	EPO				
	CI	0 389 282 A2	26.09.90	EPO				
	CJ	0 463 756 B1	02.01.92	EPO				
	CK	0 526 004 A1	03.02.93	EPO				
	CL	0 702 555 B1	27.03.96	EPO				
	CM	WO 92/11260	07.1992	PCT				
	CN	WO 91/19717	26.12.91	PCT				
	CO	WO 91/07945	13.06.91	PCT (in French)				
	CP	WO 91/07945 A1	13.06.91	PCT (English Translation)				X
	CQ	WO 92/05176	02.04.92	PCT				
	CR	WO 92/11260	09.07.92	PCT				
	CS	WO 93/23401	25.11.93	PCT				
	CT	P 19 38 016.6	28.01.71	Germany				
	CU	WO 94/28902	22.12.94	PCT				
	CV	WO 99/54331	02.04.92	PCT (in German)				
	CW	WO 99/54331	28.10.99	PCT (English Translation)				X
	CX	WO 92/05175	02.04.92	PCT				
	CY	WO 99/62905	09.12.99	PCT				
	CZ	WO 99/24433	20.05.99	PCT				
	DA	FR 2.116.302	13.07.72	France				
	DB	89/10123	02.11.89	WIPO				
	DC	91/19717	26.12.91	WIPO				
	DD	92/05175	02.04.92	WIPO				
	DE	92/05176	02.04.92	WIPO				
	DF	93/23401	25.11.93	WIPO				
	DG	94/19351	01.09.94	WIPO				
	DH	98/16644	06.06.96	WIPO				
	DI	96/16657	06.06.96	WIPO				
	DJ	96/32379	17.10.96	WIPO				
	DK	97/03985	06.02.97	WIPO				
	DL	97/24334	10.07.97	WIPO				
	DM	97/43287	20.11.97	WIPO				
	DN	98/08848	05.03.98	WIPO				
	DO	98/15530	16.4.98	WIPO				
	DP	98/38168	03.09.98	WIPO				
	DQ	98/49166	06.11.98	WIPO				
	DR	99/00359	07/01/99	WIPO				
	DS	99/00373	07/01/99	WIPO				
	DT	99/21558	06.05.99	WIPO				
	DU	99/21831	06.05.99	WIPO				
	DV	99/42452	26.08.99	WIPO				
	DW	99/43674	02.09.99	WIPO				
	DX	99/43679	02.09.99	WIPO				
	DY	99/64333	28.10.99	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EA	Ho-Sam Ahn et al, "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity", <i>J. Med. Chem.</i> , Vol. 40, No. 14, pp. 2198-2210 (1997).	
EB	J.L. Ambrus et al, "Studies on Vasoocclusive Crisis of Sickle Cell Disease. I. Effect of Pentoxifylline", <i>Journal of Medicine</i> , Vol. 10, No. 6, pp. 445-456 (1979).	
EC	Bradley D. Anderson et al, "Preparation of Water-Soluble Compounds Through Salt Formation", <i>The Practice of Medicinal Chemistry</i> , C. G. Wermuth, Ed., Academic Press, New York, pp. 739-754 (1996).	
ED	M.I. Argel et al, "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein Kinase Activity and Cyclic Nucleotide Levels", <i>J. Mol. Cell Cardiol</i> , Vol. 12, No. 10, pp. 939-954, Abstract (1980).	
EE	Hans-Joachim Arnold et al, "Pharmacopoeia of Traditional Medicine in Venda", <i>Journal of Ethnopharmacology</i> , Vol. 12, pp. 35-74 (1984).	
EF	William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", <i>The Journal of Urology</i> , Vol. 145, No. 4, p. 341A, Abstract No. 516 (1991).	
EG	Joseph A. Beavo, "Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms", <i>Physiological Reviews</i> , Vol. 75, No. 5, pp. 725-748 (October 1995).	
EH	Joseph A. Beavo & David H. Reifsnyder, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", <i>Trends in Pharmacological Sciences</i> , Vol. 11, No. 4, pp. 150-155 (April 1990).	
EI	Stephen M. Berge et al, "Pharmaceutical Salts", <i>J. of Pharmaceutical Sciences</i> , Am. Pharm. Assoc. and Pergamon Press, Vol. 66, No. 1, pp. 1-19 (January, 1977).	
EJ	Anne Bowman et al, "Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle", <i>Br. J. Pharmac.</i> , Vol. 81, pp. 665-674 (1984).	
EK	V. Mironi et al, letter to ed. re. "Intracavernous Cyclic GMP Products Produces Penile Erection in Patients with Erectile Dysfunction", <i>British Journal of Urology</i> , Vol. 71, No. 3, p. 365 (March 1993).	
EL	Gary Brooker et al, "Radioimmunoassay of Cyclic AMP and Cyclic GMP", <i>Advances in Cyclic Nucleotide Research</i> , Paul Greengard et al, Eds., Vol. 10, pp. 1-33 (1979).	
EM	Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of corpus cavernosum smooth muscle", <i>Ph.D. dissertation U.C.L.A.</i> (UMI Dissertation Services Order No. 9319914) (179 pgs) (1993).	
EN	Peggy Bush et al, "Nitric Oxide Is a Potent Relaxant of Human and Rabbit Corpus Cavernosum", <i>Journal of Urology</i> , Vol. 147, pp. 1650-1655 (June 1992).	
EO	S. Carrier et al, "Erectile Dysfunction," <i>Endocrinology and Metabolism Clinics of North America: Clinical Andrology</i> , Vol. 23, No. 4, pp. 773-782 (Dec. 1994).	
EP	P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3-Methyflavone-8-carboxylic Acid", <i>Drug. Res.</i> , Vol. 38 (I), No. 3, pp. 379-382 (1988).	
EQ	J. Cortijo et al, "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including Studies with Human Bronchus", <i>Br. J. Pharmacol.</i> , Vol. 108, pp. 562-568 (1993).	
ER	Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors", <i>Br. J. Pharmacol.</i> , Vol. 106, pp. 1028-1034 (1992).	
ES	Dario Dollier et al, "The Gif System as a Tool in Medicinal Chemistry: The Oxidation of SCH57726 under GOAGG III Conditions", <i>Bioorganic and Medicinal Chemistry Letters</i> , Vol. 7, No. 11, pp. 1381-6 (1997).	
ET	Dukarm R.C., et al., (1999) The cGMP-specific Phosphodiesterase Inhibitor E4021 Dilates the Pulmonary Circulation. <i>American Journal Respir. Crit. Care Med.</i> , Volume 160:858-865.	
EU	I.J. Fishman, "Treating Erectile Dysfunction: New Approaches", <i>Drug Therapy</i> , Vol. 8, pp. 102-110 (August 1989).	
EV	Gaine S.P., et al., (1998) Primary Pulmonary Hypertension, <i>The Lancet</i> , Volume 352:719-725.	
EW	P.G. Gillespie & J.A. Beavo, "Inhibition and Stimulation of Photoreceptor Phosphodiesterases by Dipyridamole and M & B 22,948", <i>Molecular Pharmacology</i> , Vol. 36, pp. 773-781 (Nov. 1988)	
EX	J.C. Gingell, et al, "Emerging pharmacological therapies for erectile dysfunction", <i>Exp. Opin. Ther. Patents</i> , Vol. 9, No. 12, pp. 1689-1696 (1999).	
EY	Philip L. Gould, "Salt Selection for Basic Drugs", <i>Int'l J. of Pharmaceutics</i> , Elsevier, Vol. 33, pp. 201-217 (1986).	
EZ	Theodora W. Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, pp. 1-9 (1981).	
FA	Alain Gregoire, "Viagra: on release", <i>BMJ</i> , Vol. 317, p. 759-760 (Sept. 19, 1998).	

	FB	Hanasato N., et al. (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Pulmonary Hypertension in Rats, <i>American Journal of Physiol.</i> , Volume 277 (Lung Cell. Mol. Physiol. 21): L225-L232.
	FC	"Pharmaceutical Coloring Agents", <i>Handbook of Pharmaceutical Excipients</i> , American Pharmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1986).
	FD	Takeru Higuchi, "Prodrug & Drug Delivery - An Overview", <i>Bioreversible Carriers in Drug Design: Theory and Application</i> , Edward B. Roche, Ed., Pergamon Press, New York, pp. 1-12 (1987).
	FE	T. Higuchi et al., Eds., "Pro-drugs as Novel Drug Delivery Systems", ACS Symposium Series 14, American Chemical Society, Wash., D.C., pp. 1-115 (1975).
	FF	F. Holmqvist et al., "Actions of 3-Morpholinosydonimine (SIN-1) on Rabbit Isolated Penile Erectile Tissue", <i>Journal of Urology</i> , Vol. 150, No. 4, pp. 1310-1315 (Oct. 1993).
	FG	F. Holmqvist et al., "Effects of the nitric oxide synthase inhibitor N ^o -nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit", <i>Acta Physiol Scand</i> , Vol. 143, pp. 299-304 (1991).
	FH	Sue Ellen Jackson et al. "Erectile Dysfunction: Therapy Health Outcomes", <i>Outcomes Research</i> , Pfizer, Inc., Elsevier (Dec. 16, 1997).
	FI	T. Katsushima et al., Structure-Activity Relationships of 8-Cycloalkyl-1,3-diprophyllxanthines as Antagonists of Adenosine Receptors, <i>J. Med. Chem.</i> , 1990, 33, pp. 1906-1910.
	FJ	Yasuo Kawanishi et al., "Double-Blind Trial of Oral Prostaglandin E, on Impotence", <i>The Japanese Urological Association</i> , Vol. 83, No. 1, Abstract, pp. 1656-1661 (Oct. 1992).
	FK	Stanley G. Korenman et al., "Treatment of Vascular Sexual Dysfunction with Pentoxyfylline", <i>J. Am. Geriatrics Soc.</i> , Vol. 41, No. 4, pp. 363-366 (April, 1993).
	FL	Robert J. Krane et al., "Impotence", <i>New England Journal of Medicine</i> , Vol. 321, No. 24, pp. 1648-1658 (Dec. 14, 1989).
	FM	Kremzer, et al., "Synth. & Biol. activity of diprophylline anal.", <i>Khim-Farm. Zh.</i> , 15/6, 59-64(1981); CAS ABS '81:632818.
	FN	W.R. Kukovatz et al., "Evidence for Cyclic GMP-Mediated Relaxant Effects of Nitro-Compounds in Coronary Smooth Muscle", <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , Vol. 310, pp.129-138 (1979).
	FO	Y.-M. Lin et al., "The rabbit as an intracavernous injection study model", <i>Urol. Res.</i> , Vol. 24, pp. 27-32 (1996).
	FP	Tom F. Lue, "Topical and Oral Agents for Erectile Dysfunction", <i>J. Formos Med. Assoc.</i> , Vol. 98, No. 4, pp. 233-241 (March 9, 1999).
	FQ	James A. Lugg et al., "The Role of Nitric Oxide in Erectile Function," <i>J. of Andrology</i> , Vol. 16, No. 1, pp. 2-4 (Jan./Feb. 1995).
	FR	E.G. McMahon et al., "Depressor and Natriuretic Effects of M & B 22,948, a Guanosine Cyclic 3',5'-Monophosphate-Selective Phosphodiesterase Inhibitor", <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 2513, pp. 1000-1005 (1989).
	FS	W. Meinhardt et al., "The influence of medication on erectile function", <i>International Journal of Impotence Research</i> , Vol. 9, pp. 17-26 (1997).
	FT	M.F. Meyer et al., "Intracavernous Application of SIN-1 in Rabbit and Man: Functional and Toxicological Results", <i>Ann. Urol.</i> , Vol. 27, No. 3, pp. 179-182 (1993).
	FU	Alvaro Morales et al., "Oral and Topical Treatment of Erectile Dysfunction", <i>Urologic Clinics of North America</i> , Vol. 22, No. 4, pp. 879-886 (Nov. 1995).
	FV	John E. Morley, "Management of Impotence, Diagnostic considerations and therapeutic options", <i>Impotence</i> , Vol. 93, No. 3, pp. 65-67, 71-72 (Feb. 15, 1993).
	FW	Murray, K.J., Phosphodiesterase V _A Inhibitors, <i>DN&P</i> 6(3), pp. 150-155, April 1993.
	FX	C. David Nicholson et al., "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", <i>Trends in Pharmacological Sciences</i> , Vol. 12, pp. 19-27 (Jan. 1991).
	FY	Nantka-Namirska, P., et al., Synteza 7-Podstawionych Pochodnych 8-aminometyl-1,3-Dwumetoksyantyny, <i>ACIA POLAN. PHARM.</i> , XXXI Nr 1, (1974) [In Polish]
	FZ	Nantka-Namirska, P., et al., Synthesis of 7-Substituted Derivates of 8-aminomethyl-1,3-dimethylxanthine, <i>Acta Polon. Pharma</i> , 31(1):5-11 (1974) [English Translation]
	GA	Ohnishi M., et al., (1999) E4021, a Selective Phosphodiesterase 5 Inhibitor. Potentiates the Vasoconstrictor Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. <i>Journal of Cardiovascular Pharmacology</i> , Volume 33:619-624.
	GB	Elizabeth Palmer, "Making the love drug", <i>Chemistry in Britain</i> , Vol. 35, No. 1, pp. 24-26 (Jan. 1999)
	GC	Pfizer, "Erectile Dysfunction", 1998 Annual Report, p. 21.
	GD	Physicians' Desk Reference, Medical Economics Company, 55 th Ed., pp. 2534-37 (2001)
	GE	Physician's Desk Reference, Medical Economics Company, 46th Ed., pp. 1099-1100 (1992).
	GF	Physician's Desk Reference, Medical Economics Company, 46th Ed., Product Identification Dayton Hiram Tablets and Yohimex Tablets, pp. 409, 905 & 1190 (1992)

GG	Jacob Rajfer et al, "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission", <i>New England Journal of Medicine</i> , Vol. 326, No. 2, pp. 90-94 (Jan. 9, 1992)
GH	J. Reiser et al, "The Effect of Zærinast (M&B 22, 948, an Orally Absorbed Mast Cell Stabilizer) on Exercise-Induced Asthma in Children", <i>Br. J. Dis. Chest.</i> , Vol. 80, pp. 157-163 (1986)
GI	Remington's Pharmaceutical Sciences, "Coloring, Flavoring and Diluting Agents", 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., pp. 1288-1300 (1990)
GJ	Remington's Pharmaceutical Sciences, 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., pp. 1519-1712 (1990)
GK	Alan Riley, "Oral Treatments for Erectile Dysfunction", <i>International Journal of STD & AIDS</i> , Vol. 7, Suppl 3, pp. 16-18 (1996)
GL	N.I. Romanenko et al, "Synthesis and biological activity of 3-methyl, 7- or 8-alkyl-, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines", <i>Chemical Abstracts</i> , 106: 95577n (1986)
GM	Raymond C. Rosen et al, "The process of care model for evaluation and treatment of erectile dysfunction", <i>International Journal of Impotence Research</i> , Vol. 11, pp. 59-74 (1999)
GN	David P. Rotella et al, "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction", <i>J. Med. Chem.</i> , Vol. 43, No. 7, pp. 1257-1263 (2000)
GO	Robin M. Rudd et al, "Inhibition of Exercise-Induced Asthma by an Orally Absorbed Mast Cell Stabilizer (M & B 22,948)", <i>Br. J. Dis. Chest</i> , Vol. 77, pp. 78-84 (1983)
GP	Richard Sachse et al, "Safety, Tolerability and Pharmacokinetics of Bay 38-9456 in Patients with Erectile Dysfunction", <i>Journal of Urology</i> , Vol. 163, No. 4, p. 204 (May 2000)
GQ	T. Saeki & I. Saito, "Isolation of Cyclic Nucleotide Phosphodiesterase Isozymes from Pig Aorta", <i>Biochemical Pharmacology</i> , Vol. 46, No. 5, pp. 833-839 (1993)
GR	Junichi Shlimada et al, "A Convenient Synthesis of Tricyclic Purine Derivatives", <i>J. of Heterocyclic Chemistry</i> , Vol. 30, pp. 241-246. (1993)
GS	Christian G. Stief et al, "Preliminary Results with the Nitric Oxide Donor Linsidomine Chlorhydrate in the Treatment of Human Erectile Dysfunction", <i>The Journal of Urology</i> , Vol. 148, No. 5, pp. 1437-1440 (Nov. 1992)
GT	Christian G. Stief et al, "Preliminary report on the effect of the nitric oxide donor SIN-1 on human cavernous tissue <i>In vivo</i> ", <i>World J. Urol.</i> , Vol. 9, pp. 237-239 (1991)
GU	Christian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) Inhibitors on Human and Rabbit Cavernous Tissue <i>In Vitro</i> and <i>In Vivo</i> ", <i>J. of Urology</i> , Am. Urological Assoc., Vol. 159, pp. 1390-1393 (1998)
GV	A. Taher et al, "Phosphodiesterase Activity in Human Cavernous Tissue and the Effect of Various Selective Inhibitors", <i>The Journal of Urology</i> , Vol. 149, No. 4, p. 285 (Abstract) (April 1993)
GW	A. Taher et al, "Cyclic Nucleotide Phosphodiesterase Activity in Human Cavernous Smooth Muscle and the Effect of Various Selective Inhibitors", <i>Int. J. Impotence Res.</i> , Vol. 4, Suppl. 2, p.11 (1992)
GX	Yoneda, F. et al, A New Synthesis of Substituted 8-Aminopurine Derivatives, <i>Bulletin of the Chemical Society of Japan</i> , Vol. 46, pp. 1836-1839 (1973).
GY	Yoshinatsu Takahashi et al, "Pharmacological Effects of Adenosine on Canine Penile Erection", <i>Tohoku J. Exp. Med.</i> , Vol. 165, pp. 49-58 (1991)
GZ	Youssef, S. et al., Purines XIV. [1] Reactivity of 8-Bromo-3-9-dimethylxanthine Towards Some Nucleophilic Reagents, <i>J. Heterocyclic Chem.</i> , 35, 949 (1998).
HA	Harvey C. Taud et al, "Relationship between Contraction and Relaxation in Human and Rabbit Corpus Cavernosum", <i>Urology</i> , Vol. 42, No. 6, pp. 698-704 (Dec. 1993)
HB	W. Joseph Thompson, "Cyclic Nucleotide Phosphodiesterases: Pharmacology, Biochemistry and Function", <i>Pharmac. Ther.</i> , Vol. 51, pp. 13-33 (1991)
HC	Flavio Trigo-Rocha et al, "The Role of Cyclic Adenosine Monophosphate, Cyclic Guanosine Monophosphate, Endothelium and Nonadrenergic, Noncholinergic Neurotransmission in Canine Penile Erection", <i>Journal of Urology</i> , Vol. 149, No. 4, pp. 872-877 (April 1993)
HD	Flavio Trigo-Rocha et al, "Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs", <i>Am. J. Physiol.</i> , Vol. 264, pp. H419-H422 (1993)
HE	Flavio Trigo-Rocha et al, "Intracellular Mechanism of Penile Erection in Monkeys," <i>Neurology and Urodynamics</i> , Vol. 13, pp. 71-80 (1994)
HF	Flavio Trigo-Rocha et al, "The Effect of Intracavernous Injection of Potassium Channel Openers in Monkeys and Dogs," <i>Int. J. of Impotence Research</i> , Smith-Gordon, London, Vol. 7, pp. 41-48 (1995)
HG	Flavio Trigo-Rocha et al, "Sodium Nitroprusside: Physiologic Effects as a Nitric Oxide Donor in Three Species," <i>Int. J. of Impotence Research</i> , Smith-Gordon, London, Vol. 7, pp. 49-56 (1995)
HH	Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Diagnosis and Treatment of Erectile Dysfunction," <i>Urology</i> , Vol. 44, No. 4, pp. 553-556 (Oct. 1994)

Page 6 of 6

HI	Subbarao Vermulapalli et al, "Antiplatelet and Antiproliferative Effects of SCH 51866, a Novel Type 1 and Type 5 Phosphodiesterase Inhibitor", <i>Journal of Cardiovascular Pharmacology</i> , Vol. 28, pp. 862-869 (1998)
HJ	Richard J. Weiss, "Effects of Antihypertensive Agents on Sexual Function," <i>Am. Family Physician</i> , Vol. 44, No. 6, pp. 2075-2082 (Dec. 1991)
HK	E. Douglas Whitehead et al, "Treatment alternatives for impotence", <i>PGM Symposium</i> , Vol. 88, No. 2 pp. 139-149, 152 (August 1990)
HL	Chackalamannil, Application # 09/940,760. Filed 08/28/2001
HM	Asberom, Application #10/227,778. Filed 08/26/2002
HN	Asberom, Application #10/290,011. Filed 11/07/2002
HO	PCT International Search Report for PCT US 01/28983 mailed 02/15/2002
HP	XP-002188426. Synthesis and biological activity of 3-methyl,7- or 8-alkyl-, 7, 8-dialkyl, heterocyclic, and cyclohexylaminoxanthines, 6001 Chemical Abstracts, Columbus, Ohio, US, No. 106:95577n, (1987).
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

48737_1.DOC

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.